This information is for Healthcare Professionals only.
This promotional video was organised and funded by Bristol Myers Squibb. BMS medicines and/or production information may be discussed.
Click here for Prescribing Information
This BMS-sponsored promotional symposium, presented at the European Crohn’s and Colitis Organisation (ECCO) Congress 2024, presents a thought-provoking view on the latest developments in therapeutic modalities for ulcerative colitis (UC).
‘Early Action, Major Impact: S1Ps for the Moderate Ulcerative Colitis Patient’ highlights the broad spectrum of therapeutic modalities within the current treatment landscape in managing patients progressing to moderate-to-severe UC, and reviews the latest data from clinical studies of S1P receptor modulators.
Prof. Remo Panaccione and Prof. Marla Dubinksy address the current limitations of traditional UC treatments and the importance of early intervention in the disease course. Discussion continues to reflect on the positioning of S1P receptor modulators early in the treatment algorithm.
Prof. James Lindsay reviews the latest clinical trials and real-world evidence of S1P receptor modulators including the 4-year data from the TRUE NORTH OLE1 trial which evaluates the long-term efficacy and safety data of ozanimod▼ of patients with moderate-to-severe UC.
Job code: IMM-GB-2400112
Date of Prep: April 2024
Ozanimod is indicated for the treatment of adult patients with moderately-to-severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Click here to view ‘ECCO 2023 Symposium – Multidisciplinary Perspectives in UC: A Closer Look at S1P Receptor Modulators‘
